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1. Introduction  
Three decades after the discovery of the Human Immuno deficiency Virus (HIV) and its 
causal relationship with Acquired Immune Deficiency Syndrome (AIDS), HIV/AIDS 
continues to be a global burden,  with more than 60 million people being infected resulting 
in approximately 25 million deaths. The devastating impact of the HIV/AIDS pandemic on 
morbidity and premature mortality on families, communities and societies is most 
noticeable in resource limited countries that bear the brunt of the disease burden.  
By the mid-1990s, following the introduction and success of the life prolonging combination 
of antiretroviral (ARV) treatment (ART), also known as Highly Active Anti-Retroviral 
Therapy (HAART), transformed HIV-1 from being an “inherently untreatable” (Broder, 
2010) infectious agent to one highly susceptible to a range of therapies. Through global 
solidarity, political will, effective government and private agency partnerships, ART has 
become increasing accessible in resource constrained settings, significantly reducing AIDS-
related morbidity and mortality. Despite these major advances in the scale-up of ART 
provision, the continued spread of HIV remains a challenge in many resource-rich and poor 
countries, and preventing sexual transmission of HIV remains a public health priority.  
A key lesson in terms of altering pandemic trajectories at a country level and globally has 
been the importance of understanding the local epidemic with regard to the virus, modes of 
transmission and populations most impacted. This will provide information to customize 
targeted interventions. Recent research on HIV prevention strategies highlights the 
increasing opportunities available and progress made to prevent  HIV transmission, 
however, implementing these interventions remain a challenge.  
This chapter reviews the complex diversity of the evolving HIV pandemic, and potential 
interventions, strategies and challenges in planning access to prevention programmes to 
alter the course of the disease worldwide.  
2. Epidemiology of HIV/AIDS: Recent trends   
Current estimates by the Joint United Nations Program on HIV/AIDS (UNAIDS) suggest 
a declining trend in the number of new infections due to a combination of factors, 
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including HIV prevention efforts and the natural course of the epidemic. By the end of 
2009, globally an estimated 33.3 million (range 31.4 million–35.3 million) people were 
living with HIV, with 2.6 million (range 2.3 million–2.8 million) new HIV infections and 
1.8 million (range 1.6 million–2.1 million) deaths from AIDS  occurred. However, in 
several regions and countries  new HIV infections increased by more than 25% (Eastern 
Europe and Central Asia) or has remained stable (Western, Central and North America). 
In some countries there is evidence of a resurgence of HIV in men who have sex with men 
(MSM), and high rates of HIV transmission continue to occur in networks of people who 
inject drugs through shared needles and their sexual partners. Worldwide majority of all 
new HIV infections occur in women and account for more than 45% in the 15–24 year age 
groups each year.  
Sub-Saharan Africa is home to approximately 10% of the world’s population, yet bears a 
disproportionate burden of the disease, accounting for 67% of the global HIV infections, 
with over 80% occurring in women. While there has been some decline in the recent number 
of new HIV infections, HIV incidence and mortality rates remain unacceptably high, with 
more than 75% of global AIDS related deaths occurring in this region. Despite the much 
later appearance of the epidemic in Asia, the region home to approximately 60% of the 
world’s population, the epidemic patterns vary between and within countries. HIV 
prevalence is increasing in low-prevalence countries such as the Philippines, Bangladesh 
and Pakistan where injecting drug use (IDU) is the main mode of HIV transmission. In 
Thailand the prevalence is close to 1% and the epidemic appears to be stable, while in China 
five provinces account for more than 50% of infections. In India the prevalence has remained 
below 1% and remains concentrated in IDU’s, sex workers and their clients. Although the 
numbers of new HIV infections are increasing in certain parts of South-East Asia, the 
national adult HIV prevalence is likely to mask growing local concentrated epidemics. In 
many eastern European countries and in central Asia, the number of HIV/AIDS cases is 
rapidly increasing, with an estimated 70% of those infected live in the Russian Federation. 
The trends in HIV infections in Latin America have changed little in the past decade, with 
the largest epidemic being in Brazil (adult prevalence 2%), which, due to widespread access 
to ART, has seen a decline in the number of deaths. Throughout North America, Western 
and Central Europe, the HIV epidemic has remained stable for several years, as access to 
life-prolonging ART has led to an increase in the number of people living with the disease. 
However, recent data suggests that new epidemics are emerging among young women 15 to 
24 years of age and in minority ethnic groups. Of concern are the growing epidemics in the 
Oceania region, where the number of new infections has doubled, and over 70% of HIV 
infected people live in Papua New Guinea. In Australia and New Zealand, the HIV 
prevalence has remained below 1% and is concentrated among MSM. While the epidemic in 
the Caribbean region appears to have stabilized, the majority of people living with HIV are 
concentrated in the Dominican Republic and Haiti, with MSM accounting for more than 
80% of all reported HIV cases. The epidemics in the Middle East and North Africa regions 
have not been well characterized, as there is a paucity of surveillance data, with adult HIV 
prevalence not exceeding 0.3%. Figure 1 shows the current worldwide burden of HIV 
infection (Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health 
Organization (WHO). 2010).  
Considerable progress has been made towards the Millennium Development Goal (MDG) 6, 
“to halt and begin to reverse the HIV epidemic” (United Nations Millennium Development 
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Fig. 1. Worldwide burden of HIV infection (Joint United Nations Programme on HIV/AIDS 
(UNAIDS) and World Health Organization (WHO). 2010) 
Goals., 2000) through the Declaration of Commitment made in the 2001 United Nations 
General Assembly Special Session on HIV/AIDS (UNGASS) where member states 
committed to enhance, co-ordinate and intensify regional, national and international efforts 
to comprehensively address the problem of HIV/AIDS in all its aspects (United Nations 
General Assembly., 2001). This commitment was intensified more recently through the 2006 
United Nations Political Declaration on HIV/AIDS. Prevalence appears to have stabilized or 
show a downward trend in many countries, yet worldwide, HIV continues to 
disproportionately affect women and young girls. For example  in southern Africa, where 
more women than men are living with HIV, young women aged 15–24 years are as much as 
eight times more likely than men to be HIV positive (Gouws, Stanecki, Lyerla, & Ghys, 
2008). Therefore, any decline in new infections in young women in this age group will 
significantly impact the epidemic globally.  
3. Know your HIV epidemiological typology and modes of transmission   
The HIV epidemic has evolved differently around the world, and it is important to 
understand the evolving transmission dynamics at country, regional and local level to 
prioritize and tailor appropriate prevention interventions. Epidemics are highly dependent 
on when the virus was introduced into a community, the sexual networks, risk behaviours 
of partner change, concurrent or overlapping sexual relationships, bridging populations, 
mobile populations through migratory work systems and gender imbalances. In addition, 
poor infrastructure development, poorly skilled populations, poverty, widespread hunger 
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and social instability in many countries have impacted and aided the spread of HIV. The 
country level epidemics are described and classified by their current state, ranging from 
being low-level, to concentrated, then generalised and finally hyper-endemic generalised 
based on the HIV prevalence in different populations  (Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2007a). 
Countries experiencing low-level epidemics are those where HIV has been prevalent for 
many years but is confined to most-at risk populations, often amongst individual with high 
risk behaviour in specific groups such as female sex workers (FSW), IDU and MSM. The 
sexual networks of risk in this epidemic state are not diffuse, with low levels of partner 
change or concurrent sexual relationships, or the virus may have been introduced only very 
recently. Generally, the HIV prevalence does not exceed 5% in any defined most-at-risk 
population and 1% in pregnant women, and this type of epidemic is seen in Senegal in West 
Africa and in parts of central Europe. 
Concentrated epidemics are characterized by HIV spreading within a defined sub-
population such as MSM, IDU or sex workers and their clients. HIV remains at high levels in 
these sub-populations and is not well established in the general population, suggesting 
active networks of risk are within a defined sub-population that do not bridge or cross into 
other populations. The disease burden and infection rates vary substantially between 
countries, and HIV prevalence is consistently above 5% in most-at risk populations, yet 
remains below 1% in pregnant women. Within these concentrated epidemics, the mode of 
transmission may change as epidemics within sub-populations continue. The epidemic in 
the United States of America, Canada, Central and South America, Europe, Australasia, 
China, many countries of South East Asia and parts of Africa (Ghana) represent this type of 
epidemic. Most countries have geographical and regional variations in their HIV epidemics 
and can experiences a mix of epidemics which evolve over time from low level epidemics to 
concentrated epidemics.  
In generalized epidemics, such as in most countries in sub-Saharan African, HIV is firmly 
established in the general population and not dependent on the most-at-risk groups. The 
epidemic is sustained through heterosexual transmission; countries report an HIV 
prevalence of about 5% in adults and in excess of 5% among pregnant women with a 
concomitant epidemic of perinatally acquired infections. Southern Africa remains at the 
epicentre of the global AIDS epidemic and has the characteristic of a hyper-endemic 
generalized epidemic, with an adult HIV prevalence exceeding 15% in the general 
population [Swaziland (25.9%), Botswana (24.8%), Lesotho (23.6%), Mozambique (16.1%), 
South Africa (17.8%), Zambia (13.5%) and Zimbabwe (14.3%)] (Joint United Nations 
Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). 2010). New 
infection rates are higher than 5% per year despite high and increasing morbidity and 
mortality rates, with all sexually active persons having an elevated risk of acquiring HIV 
infection. These epidemics are driven through extensive heterosexual multiple concurrent 
partner relationships, specifically when young women have sexual relationships with men 
who are older through intergenerational or cross-generational relationships which often 
involves the exchange of goods or money through transactional sex.  
4. Principles for HIV prevention   
As the HIV epidemics within countries and regions may not be homogeneous in typology, 
may evolve over time from a low level scenario through concentrated and generalized 
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phases to a hyper-endemic scenario, or remain relatively stable or decline, the design of HIV 
programs must be tailored to shape the course of the epidemic. To ensure an effective 
national HIV prevention response, “strong, informed and committed leadership, 
coordination and accountability” are required to include the most vulnerable and to 
meaningfully include those living with HIV. UNAIDS guidelines encourage countries to 
“know your epidemic and your current response”, which requires identifying the key 
drivers of the epidemic, focusing on the relationship between the epidemiology of HIV 
infection and the behaviours and social conditions that impede their ability to access, as well 
as to use HIV information and services. Knowledge of the epidemic provides the basis for 
determining the response, and enables countries to “match and prioritize your response” by 
identifying, selecting and funding those HIV prevention measures that are most appropriate 
and effective for the country in relation to its specific epidemic scenario. The key to this 
response must enable countries to “set ambitious, realistic and measurable prevention 
targets” in relation to the epidemic scenario, to synthesize essential prevention measures 
required to “tailor your prevention plans” and “utilize and analyse strategic information” to 
modify, enhance or strengthen the HIV prevention measures that are likely to produce the 
greatest impact in each setting by promoting access to HIV prevention, treatment, care and 
support.  
5. Preventing sexual transmission of HIV   
Despite the many diverse HIV epidemics globally, each with its own dynamic characteristic, 
young women continue to be at considerable risk of infection. Sexual transmission remains 
the primary route of infection worldwide, accounting for approximately 80% of all cases. 
Transmission occurs through any unprotected penetrative sex act where one partner is 
infected with HIV (discordant sex acts), with the risk of becoming infected being dependent 
on the background prevalence in the population, the number of concurrent partnerships, the 
frequency of change of sex partners, the frequency of unprotected sex acts, the type of sex 
act (receptive anal versus receptive vaginal), and the amount of virus (viral dose) present in 
the semen, vaginal, or cervical secretions of the infected partner. The viral dose is dependent 
on the stage of HIV infection, with individuals who have recently been infected having the 
highest virus load, followed by those with a concomitant sexually transmitted disease, 
followed by those with advancing HIV disease, having a high concentration of HIV receptor 
cells at the site of infection, which increases the risk of acquiring and transmitting HIV 
(Abu-Raddad & Longini, 2008; Gray, et al., 2001; Pettifor, Macphail, Rees, & Cohen, 2008; 
Pilcher, et al., 2007; Pilcher, et al., 2004; Quinn, et al., 2000).  
In generalized hyper-endemic epidemics, HIV infection extends beyond discrete 
populations of MSM, IDU and sex workers; the background prevalence of HIV is a 
significant risk factor for HIV acquisition. The majority of HIV-infected individuals are 
unaware of their HIV status which remains a barrier for both treatment access and 
prevention. For many women, being married is the single biggest risk factor for HIV 
acquisition. Concurrent and multiple sexual partnerships, low condom use, low levels of 
male circumcision, early sexual debut, transactional sex, age disparate or 
intergenerational sex relationships, anal sex,  non-injecting drug use, alcohol use, and 
sexual violence increase HIV risk disproportionately in women and help sustain high 
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rates of HIV infection in these settings. (Dunkle, et al., 2007; Harrison, Cleland, & 
Frohlich, 2008; Jewkes, et al., 2006; Kalichman, et al., 2007; Kenyon C & Badri M, 2009; 
Leclerc-Madlala, 2008; Lurie, Williams, & Gouws, 1997; A. E. Pettifor, van der Straten, 
Dunbar, Shiboski, & Padian, 2004; Sikweyiya & Jewkes, 2009; Van Tieua & Koblina, 2009; 
Zablotska, et al., 2009). To appreciate the complexities of HIV transmission, it is important 
to better understand individual behaviours and sexual networks within a broader context 
of political, economic, and social forces that enable or serve as barriers to HIV risk 
(Rothenberg 2009). While there are a number of issues that need to be addressed in order 
to prevent the spread of HIV infection, developing promising new preventative 
technologies could directly benefit young girls and women who account for more than 
50% of new infections worldwide.  
5.1 Health sector interventions  
In many health care settings, HIV counselling and testing, peer education, treatment of 
sexually transmitted infections (STIs) as well as condom promotion and provision are 
delivered as integrated HIV prevention packages. Despite the 90% clinical effectiveness of 
preventing HIV transmission, the public health use of condoms is confined predominantly 
to FSW and MSM. Patterns of male condom use as a barrier method are heavily influenced 
by the form of partnerships. Condom use is generally highest in commercial sex work and 
lower in non-commercial and regular partnerships. In long-term or regular partnerships, 
condom use is often inconsistent and low among those at highest risk where the partner is 
not monogamous (Moyo, Levandowski, MacPhail, Rees, & Pettifor, 2008). In many 
relationships, women’s inability to influence men reflects the fact that men usually dominate 
women’s sexual lives and often impose whether intercourse will take place or not, and 
whether a condom will be used. As male condom use is largely dependent on male partners, 
the female condom, a female-initiated HIV prevention method if used correctly and 
consistently, can potentially help women to protect themselves from becoming infected with 
HIV. However, although the female condom allows partners to share the responsibility of 
condom use, it still requires some degree of male co-operation. As men are involved in 
sexual transmission of HIV either through heterosexual transmission or through MSM, 
men’s behaviour is strongly influenced by concepts of masculinity. It is important that 
programs are designed to influence and persuade men to be responsible and protective to 
themselves and their partners.  
The sexual transmission of HIV infection within partnerships seems to be facilitated by 
several STIs. Epidemiological studies suggest a synergistic bidirectional relationship 
between STIs and HIV. STIs in HIV-uninfected men and women increases their 
susceptibility to HIV infection and similarly in infected individuals with HIV and STIs there 
is enhanced shedding of HIV in genital secretions (Rottingen, Cameron, & Garnett, 2001). 
Thus far only one community based randomised trial conducted in Mwanza demonstrated 
the effectiveness of enhanced case detection and treatment of symptomatic curable STI’s 
(chancroid, syphilis, gonorrhoea, chlamydial infection, and trichomoniasis) in primary 
health-care services to impact on HIV incidence. The Mwanza trial demonstrated a 
significant 42% reduction in HIV acquisition in intervention communities (Hayes, et al., 
1995), while no effect of an STI intervention on HIV incidence was reported from other trials 
(Ghys, et al., 2001; Kamali, et al., 2002; Kaul, et al., 2004; Wawer, et al., 1998). The recently 
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reported trials on herpes simplex virus type 2 (HSV-2) suppressive therapy for preventing 
HIV acquisition also failed to demonstrate effectiveness (Celum, et al., 2008; Celum, et al., 
2010; Watson-Jones, et al., 2008). While several factors may have contributed to these 
contrasting results, treatment of STIs remains a public health priority.  
5.2 HIV counselling and testing 
HIV counselling and testing (HCT) has been an important prevention tool, and has been 
hypothesized that  knowing one’s  status allows positive people to protect others from being 
infected and those who are negative to protect themselves from infection (The Voluntary 
HIV-1 Counseling and Testing Efficacy Study Group., 2000). As HIV is predominantly 
transmitted sexually and linked to MSM’s, it has been surrounded by stigma and 
discrimination. Paradoxically, HIV testing, counselling and social support has provided 
limited confidentiality to those accessing these services and testing positive. A major hurdle 
for HIV infected young women to access prevention of mother to child transmission services 
following HIV counselling and testing is fear of stigma, discrimination and violence, further 
stigmatizing this age group. More recent studies have demonstrated that lack of access to 
HIV counselling and testing services remains a significant barrier to expanding access to 
treatment, particularly in developing countries. Efforts are under way in many countries to 
enhance acceptability, increase uptake, widen accessibility and provide an entry point to 
care and support for HIV positive individuals. The innovative approaches of provider-
initiated HCT in health care settings (Joint United Nations Programme on HIV and AIDS 
and World Health Organization., 2007), and the client-initiated community based 
approaches (Coates, Richter, & Caceres, 2008; Khumalo-Sakutukwa, et al., 2008)  are likely to 
promote knowledge of HIV status fundamental to accessing treatment, preventing onward 
transmission and promoting prevention. Despite the expansion of services, knowledge of 
HIV status remains low. 
5.3 Microbicides and Pre-exposure prophylaxis (PrEP) 
Female-controlled methods of HIV prevention are urgently needed, as the only proven 
method of consistent male or female condom use is dependent on male co-operation and 
compliance. Research into the development of microbicides (gel or cream) that could be 
applied to the vagina without a partner knowing, and which would prevent HIV infection, 
has received unprecedented attention and support. The over 60 candidate microbicides in 
development and 11 clinical trials testing six non-virus specific products have produced 
disappointing results, with none demonstrating a protective effect for HIV. The six 
candidate microbicides include nonoxynol-9 (N9) (Van Damme, et al., 2002), SAVVY® 
(C31G; Cellegy Pharmaceuticals, USA) (Feldblum, et al., 2008; Peterson, et al., 2007), 
cellulose sulfate (CS) (Van Damme, et al., 2008), Carraguard® (PC-515; Clean Chemical 
Sweden) (Skoler-Karpoff, et al., 2008), PRO 2000 (Endo Pharamceuticals, USA) (Abdool 
Karim, et al., 2011; Kamali, et al., 2010) and BufferGel® (ReProtect LLC, USA)(Abdool 
Karim, et al., 2011).  
Based on pre-clinical studies in different animal models, multiple studies have established 
tenofovir (antiretroviral, a nucleotide reverse transcriptase inhibitor) as a promising 
antiretroviral agent whether administered as pre-exposure or post-exposure prophylaxis to 
prevent simian immunodeficiency virus (SIV) (Tsai, et al., 2000; Van Rompay, 2010; Van 
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Rompay, et al., 2004), The recent major breakthrough and promising results from the 
CAPRISA 004 trial of 1% tenofovir  gel used intravaginally to prevent HIV acquisition in 
women are welcomed (Abdool Karim, et al., 2010). The trial was the first phase 11B proof-of-
concept study of an ARV in which 889 HIV uninfected; sexually active 18-40 year old, urban 
and rural women were randomly assigned to receive either placebo or tenofovir containing 
gel for the study duration. Women were prescribed to insert gel vaginally within 12 hours 
before and after having sex, and to use not more two gels within 24 hours. Of the 444 
women on the placebo gel, 60 women became HIV infected while 38 of the 445 women in 
the tenofovir gel arm became HIV infected. The overall effectiveness was 39%, while 54% 
were protected when they adhered to using the gel as prescribed, covering more than 80% 
of sex acts, and 28% were protected when fewer than 50% of sex acts were covered. The 
added important finding of this trial was the absence of viral resistance, its safety and more 
importantly, the effectiveness of tenofovir gel to reduce the acquisition of HSV-2 infections 
by 51%. This finding is important as the risk of HIV acquisition increases to a large extent in 
women who are HSV-2 infected (Tobian & Quinn, 2009; Wald & Link, 2002).  
Shortly after the release of the CAPRISA 004 trial results, the iPrEx (Pre-exposure 
Prophylaxis Initiative) trial demonstrated a 44% protection against HIV acquisition 
among MSM following the daily single oral dose of the ARV drug of Truvada® which 
contains two drugs : tenofovir disoproxil fumarate (TDF-300 mg) and emtricitabine (FTC-
200 mg) (Grant, et al., 2010). The iPrEx study was a double-blind, placebo-controlled, 
Phase III clinical trial which enrolled 2,499 HIV-negative male volunteers and took place 
at 11 research sites in Brazil, Ecuador, Peru, South Africa, Thailand and the United States. 
There were 64 HIV infections among the 1,248 participants who received a placebo pill, 
while 36 HIV infections among those who received Truvada®. Among participants who 
used the pill more than 90 percent of days, protection against HIV acquisition was over 
72%. However, the iPrEX study found no evidence that Truvada® taken orally provided 
protection against HSV-2 infection.  
The success of these two trials provides growing evidence of the potential of ARV’s to 
prevent sexual transmission of HIV. The efficacy and safety of ARV’s are being tested in 
several oral and topical PrEP clinical trials. The  FEM PrEP trial tested a daily single oral 
dose of  Truvada® for heterosexual HIV prevention in 3900 high risk HIV uninfected 
women, 18-35 years of age in Kenya, Malawi, Tanzania, Zambia and South Africa. However, 
an interim review of the results of the FEM PrEP trial has established that Truvada® tablets 
taken orally was not able to demonstrate a protective effect in women against HIV infection, 
thus Truvada® may not be as effective in preventing HIV in  women compared to its proven 
effectiveness in preventing HIV  infection in MSM. 
The Centre for Disease Control (CDC) BangkokTenofovir Study is testing the daily single 
oral dose of tenofovir in approximately 2400 HIV uninfected IDU in Thailand. Despite the 
disappointing FEM PrEP trial results, the CDC TDF2 PrEP study, a randomised, placebo  
controlled trial examined the safety and effectiveness of a daily single oral dose of Truvada® 
for reducing the risk of HIV acquisition among 1200 heterosexual men and women at two 
sites in Botswana. The study enrolled approximately 1200 participants and randomly 
assigned to one of two arms: 601 were assigned to take Truvada® tablet and 599 were 
assigned to receive a placebo. In the primary trial analysis there  were nine HIV infections 
among the participants assigned to Truvada® compared to 24 infections among those 
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assigned to placebo, translating to a 62.6% (95% CI, 21.5 to 83.4; P= 0.0133) reduction in the 
risk of HIV infection among those receiving Truvada® . 
Similarly the University of Washington ‘s Partners PrEP Study was a randomised, placebo 
controlled trial of daily single oral dose of tenofovir or Truvada® for the prevention of HIV-
1 acquisition among HIV-1 seronegative partners in heterosexual HIV-1 sero-discordant 
partnerships. In the 4758 sero-discordant heterosexual couples in Kenya and Uganda, a total 
of 78 HIV infections occurred in the study: 18 among those assigned to tenofovir, 13 among 
those assigned to Truvada® , and 47 among those assigned to the placebo. Thus, those who 
received tenofovir had an average of 62% fewer HIV infections (95% CI 34 to 78%, P=0.0003) 
and those who received  Truvada®  had 73% fewer HIV infections (95% CI 49 to 85%, 
P<0.0001) than those who received placebo. 
In 5029 sexually active, HIV uninfected women, 18-40 years of age in Malawi, Zambia, 
Zimbabwe, Uganda and South Africa the VOICE (Vaginal and Oral Interventions to Control 
the Epidemic) trial is not only testing the daily single oral dose of tenofovir or Truvada®  
but also the vaginal tenofovir gel formulation. The trial design is important for determining 
how each product works compared to its control and which approach women may prefer. 
The trial is expected to complete follow-up in June 2012, by which time women would have 
used the assigned allocation for at least one year and some for nearly three years. The trial 
results are expected to be available in early 2013. More importantly, the development of HIV 
prevention products in the form of vaginal rings and injections may provide alternate 
modes of delivery possibly providing protection for longer duration. The planned Phase III 
Dapivirine ring study will expand the spectrum of ARV’s available, with an alternate 
delivery mode for HIV prevention. The diverse populations, including heterosexual men 
and women in the ongoing clinical trials, would provide further evidence for HIV protection 
in different at-risk groups, although a key question to be addressed is whether the optimal 
drug level would be achieved if ARV’s taken orally or inserted vaginally to provide 
maximum protection .  
Both tenofovir and Truvada® are approved by the United States Food and Drug 
Administration (FDA) to treat HIV infection, and following long-term use, there have been 
no safety concerns. More importantly, these ARV microbicides provide hope to millions of 
women, and enables them to take responsibility and initiate its use as a female-controlled 
method to protect them from acquiring HIV. Adapting different forms of ARV’s for HIV 
prevention, whether taken orally or inserted vaginally, either daily or coitally, has a great 
potential to transform the global response to the HIV/AIDS epidemic. The confirmation of 
these innovative scientific approaches from the proof-of-concept trials using ARVs for HIV 
prevention, suggest that new HIV prevention tools are attainable, but need to be easily 
accessible and affordable to potentially alter the epidemic trajectory which remains a global 
public health priority.  
5.4 Medical male circumcision 
The biological plausibility that HIV-1 targets cells in the inner mucosal surface of the male 
human foreskin which makes it highly susceptible to HIV infection has been tested through 
three randomized controlled trials. To evaluate the effect of medical male circumcision 
(MMC), i.e. partial or complete surgical removal of the foreskin on HIV prevention, the trials 
enrolled more than 10,000 HIV uninfected men from South Africa (Auvert, et al., 2005), 
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Kenya (Bailey, et al., 2007), and Uganda (Gray, et al., 2007). After 21 to 24 months of follow-
up, all three trials demonstrated that MMC significantly decreased male heterosexual HIV 
acquisition by 41% to 66%, despite differences in age eligibility criteria, urban or rural 
settings, and surgical procedure (Auvert, et al., 2005; Bailey, et al., 2007; Gray, et al., 2007; 
Siegfried, Muller, Deeks, & Volmink, 2009). 
Based on the compelling evidence from clinical trials and modelling of data (Hallett, et al., 
2008; Williams, et al., 2006), UNAIDS and WHO have recommended that MMC be provided 
as an important intervention to reduce heterosexually acquired HIV in men, and that it be 
part of a comprehensive HIV prevention package which includes HIV testing and 
counselling services, treatment for STIs, male and female condom provision (Joint United 
Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 
2007b). 
In countries with generalised heterosexual HIV epidemics with high incidence rates, male 
circumcision rates are generally low, and for any significant public health benefit to be 
achieved, urgent scale up of MMC services should be considered (Lissouba, et al., 2010). A 
rapid public health impact would be achieved if MMC services are prioritised to age groups 
at highest risk of acquiring HIV. Nevertheless, providing MMC services to younger age 
groups will also have public health impact over the longer term. In countries with 
concentrated HIV epidemics, specific high risk populations of IDU’s and MSM should be 
targeted to achieve an individual benefit for men at high risk of sexually acquired infection. 
While the scale-up of MMC programmes has the potential to lower HIV prevalence among 
the male population, in the long term women would benefit from reducing their risk of 
exposure. 
Mathematical modelling suggests that in high burden countries in sub-Saharan Africa, with 
maximum coverage of male circumcision over a ten year period, it could avert 2 million new 
HIV-infections and 0.3 million deaths. In the 10 years thereafter, it could avert a further 3.7 
million new infections and 2.7 million deaths, demonstrating the substantial public health 
benefits of male circumcision to lessen the transmission of HIV (Williams, et al., 2006).  
Many sub-Saharan African countries have begun taking steps to increase the availability of 
MMC services, with set targets of maximum coverage to be achieved over the next five years 
despite the concerns of risk compensation, the challenges of cultural and social acceptability, 
limited financial and human resources, poor infrastructure and systems for monitoring and 
evaluating circumcision programmes (Kim & Goldstein, 2009; Weiss, Dickson, Agot, & 
Hankins, 2010). Additionally, more research is needed to determine the side effects of 
poorly performed circumcision with a risk HIV acquisition from poorly healed procedures, 
serious bleeding, risk of cross infection and damage to the penis (Lagarde, Taljaard, Puren, 
& Auvert, 2009; Schackman, 2010). As MMC provides partial protection, such programmes 
must be part of the comprehensive HIV prevention package (Hallett, et al., 2008; Joint 
United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO), 2007b).  
5.5 Antiretroviral treatment for HIV prevention  
The transmission probability of HIV is dependent on the viral load, and there is a substantial 
reduction in HIV viral load following ART initiation, with simultaneous improvement in the 
general health of the person being treated. Increasing evidence from several studies suggest 
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that following the introduction of ART, transmission of HIV declines at the individual level. 
Amongst IDU’s on ART in Vancouver, British Columbia, a decrease in the median plasma 
HIV-1 RNA concentration correlated with a decline in the incidence of HIV-1 infection. In a 
cohort study, HIV-1 transmission was 92% lower among couples in whom the index partner 
was taking ART (Donnell, et al., 2010). Extensive experience on the role of ART has been 
amongst pregnant and breastfeeding HIV positive women, with maternal ART having been 
highly successful as a prevention strategy for lowering the risk of mother to child 
transmission. Ongoing studies among sero-discordant couples will provide evidence of ART 
to lower the viral load and decreasing the risk of HIV transmission among adults.  
The potential impact of ART to significantly impact on new HIV infection rates has recently 
been modelled on data from South Africa. Mathematical modelling suggests that wider HIV 
testing, and immediate ART for those testing positive, will significantly impact on new 
infection rates (Granich, Gilks, Dye, De Cock, & Williams, 2009). While the model assumes that 
individuals will test annually for HIV, persons testing positive, commencing ART immediately 
and maintain it for life will significantly reduce the new infection from 17 per 100 people per 
year (Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health 
Organization (WHO), 2008) to 1 per 1000 people per year over the next 10 years, leading to 
eventual elimination of the epidemic. The model however, does not include the timing 
between infection, diagnosis and the introduction of ART, the acceptability of HCT, the need 
for high adherence to ART, risk behaviours of people undergoing treatment, as well as low 
level of transmission and an emerging drug-resistant virus. The risk of HIV transmission is 
generally highest during acute infection and the later stages of infection, providing some 
indication of where treatment might have its biggest prevention effect, thereby fitting into a 
comprehensive prevention approach. While the model is optimistic, it may be unattainable in 
real-world settings, as the effectiveness of ART, behavioural risk factors, HIV testing coverage, 
reluctance to commence ART for fear of stigma and discrimination and epidemiological 
scenario could have a major influence on the overall impact of HIV testing and treatment 
programs. Furthermore, more than 50% of HIV infected persons worldwide are unaware of 
their HIV status, and these figures are much higher in high burden countries. In many 
resource-poor countries, the existing strain on health care services is a major obstacle to 
initiation of ART, while in many well resourced countries, the HIV-linkage to care and 
treatment cascade dramatically declines, with many individuals requiring ART not being on 
treatment. Nevertheless there are numerous programmatic issues that need addressing prior 
to implementation of the wider HIV testing and immediate ART for those testing positive 
strategy. Research on each component will guide the programmes roll-out including 
providing evidence of the risk and benefits of early ART to individuals.  
The most convincing results and significant findings of HIV treatment as prevention come 
from the HPTN 052 study which took place at 13 sites in Botswana, Brazil, India, Kenya, 
Malawi, South Africa, Thailand, the United States and Zimbabwe. The randomised 
controlled trial enrolled 1,763 serodiscordant couples to test the effectiveness of currently 
licensed regimens of ART whether delivered early or delayed to reduce the risk of HIV 
transmission. At the time of enrolment, the HIV-infected partners (890 men, 873 women) 
had a median CD4+ T-cell count of 436 cells/mm3, ranging from 350 and 550 cells per mm3, 
while the HIV-uninfected partners tested negative for the virus. Participating couples were 
randomly assigned to one of two treatment arms. In the first group, the HIV-infected 
partners immediately began taking a combination of three ARV drugs. In the second group, 
the HIV-infected partners delayed taking ARV drugs until their CD4+ T-cell counts fell 
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below 250 cells/mm3, or an AIDS-related illness as defined by World Health Organization 
guidelines occurred. Following a scheduled interim review of the study’s safety and 
effectiveness data by the independent data and safety monitoring board (DSMB), the DSMB 
found that 28 of the HIV infections were linked through genetic testing to the HIV-infected 
partner as the source of infection. Of the 28 cases of linked HIV infection that occurred, 27 
infections were among the 877 couples in which the HIV-infected partner delayed 
antiretroviral treatment. Only one case of HIV infection occurred among the 886 couples in 
which the HIV-infected partner began immediate antiretroviral treatment. This means that 
earlier initiation of ARV drugs led to a 96% reduction in HIV transmission to the HIV-
uninfected partner (P≤0.0001). The added therapeutic benefit was the decline in the 
morbidity and mortality events; 40 events occurred in the early treatment arm compared to 
the 65 in the delayed treatment arm. There were 17 cases of extrapulmonary tuberculosis 
among HIV-infected participants in the delayed treatment arm compared with three cases in 
the early treatment arm (P=0.0013). There were 23 deaths during the study: 10 in the early 
treatment group and 13 in the delayed treatment group, a difference that did not reach 
statistical significance (National Institute of Allergy and Infectious Diseases., 2011).  
While the initial WHO treatment guidelines of November 2003 recommended that anyone 
with advanced clinical HIV disease or those with CD4+ T-cell counts less than 200 
cells/mm³ begin ART, the follow-up revision over time recommended that ART be 
considered between 200 and 350 cells/mm³. The most recent guidelines of November 2009 
recommend the initiation of ART in all patients who have a CD4+ T-cell count of less than 
350 cells/mm³, irrespective of clinical symptoms. Though several countries have adopted 
the new guidelines, most have not primarily due to cost constraints and a lack of drug 
supply (World Health Organization., 2009). 
If ART is to be considered as part of the HIV prevention program, programmatic scaling up 
of services will be required. Identifying appropriate target population; educating health 
workers; a wider availability of ART; regular HCT services; education and counselling of all 
people who test positive for HIV are key to ART initiation. Adherence counselling for 
people who agree to treatment; and regular follow-up, including ART safety assessment, 
ongoing adherence counselling, ongoing risk behaviour counselling, and testing for viral 
load rebounds and resistant virus are vital to sustaining the programme. While the roll-out 
and maintenance of such programmes pose numerous challenges, these are highly 
dependent on the commitment of ministries of health, donors, provider organizations and 
community groups. Preliminary studies from Côte d’Ivoire, San Francisco, Spain, and 
Taiwan, indicate that wider treatment is associated with fewer new HIV infections where 
ART-as-prevention occurs. In developing countries, expanding HCT services are offered by 
mobile testing units, mainly as part of provider initiated routine health care services, as an 
opportunity to rapidly identify persons to be linked to care and ART as prevention. The 
scale-up of ART provision requires critical evaluation to expand the evidence base. More 
data are needed through monitoring and evaluation that ART provides potential gains in 
preventing new HIV infections.  
5.6 Behaviour change programmes for HIV prevention 
Population based surveys have shown that young people 15 to 24 years of age are at a 
considerable risk for HIV acquisition, and account for almost 50% of new HIV infections 
worldwide. Early age of sexual debut, inconsistent or incorrect use of condoms, and 
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experimentation with alcohol and other substances, multiple, frequent and concurrent 
sexual partners significantly increase the risk of HIV acquisition.  
To reduce the incidence of HIV, behavioural change interventions have been developed and 
implemented to reduce sexual risk (Coates, et al., 2008). These approaches include broad 
and diffused dissemination of factual information about HIV, frank discussions about 
condom use, and small-group interventions following interaction and role playing to 
enhance motivation and relevant knowledge and skills. School based HIV intervention 
programmes generally provide young learners with basic knowledge and are limited to 
being informational on how to prevent being infected. In a recent meta-analysis of sexual 
risk reduction interventions that have been successful at modifying behaviours more 
broadly delaying sexual debut, increasing condom use, abstinence or reducing or delaying 
frequencies of penetrative sex, and increasing skills to negotiate safer sex and acquire 
condoms have shown to be effective. Although intervention success varied across studies, 
the benefits were evidence sustained for up to three years post intervention, across gender 
and geographic region (Johnson, Scott-Sheldon, Huedo-Medina, & Carey, 2011). HIV 
intervention programmes amongst couples and families attempt to promote risk reduction 
through innovative strategies that include motivational behaviour change.  
Behavioural science theories of using informational, motivational, and skills-based content 
to deliver interventions confirm that the efficacy of behavioural strategies together with 
motivational training providing greater condom skills training thereby encouraging condom 
use, and were more successful at decreasing the frequency of sex in younger rather than 
older adolescents. Effective behaviour change programs with comprehensive information on 
reducing HIV risk must be designed, tailored and implemented with informational, 
motivational, and skills-based content. They should be customised to address the needs and 
values of the groups they are designed to reach which will make them more likely to be 
effective at preventing HIV acquisition.  
5.7 Structural interventions for HIV prevention 
Insights into the variation in levels of risk in populations, as well as the biological and 
socioeconomic factors, are key to understanding risk of HIV acquisition and the speed at 
which HIV spreads through a population. This is dependent on a combination of structural, 
social, and political factors that shape behaviour, vulnerability, and risk. Sexual and ethnic 
practices, marginalised populations, women’s status, restrictive national policies, restricted 
access to health care, fear of stigma and discrimination are important structural ‘drivers’, 
increasing vulnerability and contributing to HIV transmission. In many countries, HIV 
prevention efforts have not succeeded, as the underlying social and structural drivers of 
HIV risk and vulnerability have not been addressed.  
Stigma and discrimination, gender inequalities, gender-based violence, human rights 
violations, mobility and economic power are the major structural drivers that hamper HIV 
prevention efforts and impede progress towards universal access to prevention and 
treatment programmes. HIV prevention efforts need to be adapted to change the root causes 
or structures that affect individual risk and vulnerability to HIV, ensuring that resources are 
targeted where they could have the greatest impact. While in many settings, structural 
interventions have addressed access to health care, sexuality and gender relations, stigma 
and discrimination; these have not been adequately evaluated at the programmatic level.  
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 
 
16
6. Combination HIV prevention programmes 
The diversity and complexity of epidemics that make up the HIV pandemic underscores the 
importance of a diverse set of responses rather than a single solution for all settings. The 
UNAIDS “know your epidemic, know your response” provides a strategic, intensified 
framework for understanding the local epidemic in terms of prevalence and what is 
contributing to its spread  (Wilson & Halperin, 2008). The proficient and competent 
planning of effective customized HIV prevention programs and monitoring their impact 
relies on strong health information systems as well as good local and national surveillance. 
The exact mix of HIV prevention, treatment, care, support strategies, and structural 
interventions is determined by this data (Horton & Das, 2008).  
While several HIV prevention interventions appear promising with mathematical modelling 
providing further optism for the intervention, no single intervention is likely to be sufficient 
to prevent transmission of HIV on a global scale. Each intervention has its strengths and 
limitations, yet the current HIV prevention landscape consists of several important but 
partially effective interventions, none having been shown to be fully protective. The 
appropriate mix for each epidemic, to identify the target populations and establish what 
coverage and saturation levels are required remain challenges for effective approaches to 
alter the current epidemic trajectories  The role of combination prevention programmes 
includes multi-level and multi-component interventions that incorporate biomedical, 
behavioural, and structural approaches which are considered highly active HIV prevention 
strategies and has been gaining increasing attention (figure 2).  
 
 
Fig. 2. Highly active HIV prevention Programme  (Coates, et al., 2008) 
The multilevel approach of combination behaviour change interventions is included into the 
HCT programme. The programmes are designed to include a range of activities to 
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encourage people to reduce their risk of being infected with HIV and to increase their 
protective behaviour. The approach aims to delay sexual debut, reduce sexual partnerships, 
reduce age-disparate relationships, encourage mutual monogamy, promote correct and 
consistent condom use, and increase the frequency of HCT. The messaging at different 
levels is to promote individual behaviour change and to encourage families, communities 
and social networks to adopt and maintain healthy norms and a supportive environment. In 
this context, at the individual level, educational, skills building and counselling can be 
delivered through small groups or schools-based HIV prevention programmes, and while 
these may be informational, they should be followed up with motivational skills-based 
programmes. Among couples, the HCT programme attempts to motivate behaviour change 
within primary and secondary relationships, and to focus on factors that are critical drivers 
of the epidemic. Concordant HIV positive couples have the advantage of joint referral for 
care, support and treatment. HCT, through a family-centred approach, has the advantage of 
easy access, reduces stigma and facilitating disclosure.  
Behaviour change can be facilitated through education programmes delivered by peer 
groups, community leadership or through networks. Involving peers groups in vulnerable 
populations of FSW, MSM, IDU, high risk men at truck stops and transport workers has 
been effective in increasing condom use and reducing STIs. Peer education programmes 
have been highly successful in increasing condom use among secondary school students. 
The involvement of community leaders to initiate HIV prevention and risk reduction 
messages, and to sustain risk reduction conversations, has been an innovative method of 
diffusing information through communities. Network-based interventions are particularly 
important in disseminating HIV risk reduction messages, as social networks have played a 
role in the transmission of HIV. Intervention information delivered through workplace 
programmes not only provide an opportunity to reach large numbers of often high risk 
individuals, but take advantage of motivational approaches and peer network support.  
In the absence of an HIV vaccine, recent evidence from biomedical interventions appears to 
be promising, although the levels of evidence have been inconsistent. While male and 
female condoms, if used correctly and consistently, have proven to be very effective in 
blocking HIV transmission during sexual intercourse, the challenges of access, availability, 
lack of negotiating skills, co-operation of male partner and gender related violence have 
been major obstacles to their use. Despite their ability to prevent transmission of HIV by 
more than 80%, there has been no impact on HIV incidence rates. The inconclusive results 
from the STI treatment trials on HIV acquisition make them difficult to interpret and to 
translate from research to policy. However, treatment of STIs remains an important public 
health benefit. The results from the three randomised trials on MMC, demonstrating the 
protective effect against HIV acquisition among men, provides sufficient available evidence 
to consider it as a public health intervention and calls for the its urgent scale up. 
The two trials of topical and oral antiretroviral compounds demonstrate the potential of  
methods that could be used for protection from HIV acquisition during sexual intercourse. 
However, research on biomedical interventions poses formidable challenges and concerns 
with implementation; product adherence and the possibility of sexual disinhibition. While 
expanding ART for HIV infected individuals to reduce infectiousness, expanding the wider 
HIV testing, and immediate ART for those testing positive strategy could have a major 
impact on HIV transmission and HIV-1 incidence. Nevertheless, strengthening and 
expanding the HIV treatment programme is expected to have substantial benefits in 
reducing morbidity, mortality and infectiousness.  
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In countries where HIV prevalence remain disturbingly high, there have been calls for 
prevention programmes to fully address social and economic factors that increase 
vulnerability, and to focus on high impact interventions. Currently, there are no research 
studies which best address the role of combination HIV prevention programmes to 
determine the appropriate mix of interventions. At the individual level, it is not clear 
whether there might be personal preferences for a particular intervention, whether choices 
might be available, individuals may require customised risk reduction options or the 
intervention may need to be tailored to different times in their lives. Even more difficult is 
the role of health care planners who have difficulty in prioritising interventions and whether 
to target specific groups or the general population, and then implementing those 
programmes. 
Within the context of a combination HIV prevention strategies, structural approaches that 
address social, economic, and political factors are deeply entrenched and difficult to change. 
However, interventions to combat gender violence, gender or income inequality and the 
social marginalisation of risk groups are long-term intervention initiatives that need to be 
supported through community and leadership involvement within the broader economic 
and social development. Structural interventions of facilitating microcredit programmes, 
involving women in opportunities to improve household economic wellbeing, their social 
capital, and reduce their vulnerability to intimate partner violence and therefore to HIV. 
Furthermore, attempts to address structural factors to reduce HIV risk are promoted 
through partnerships with non-governmental organisations, community groups and 
government agencies, but their value has been difficult to measure. Access to broader family 
planning and reproductive health care services may further empower women to take control 
of their live and reduce their vulnerability to HIV.  
7. Conclusions  
HIV prevention interventions need to be appropriate to the epidemic context and to address 
the right population groups with co-ordinated evidence and informed strategies that work 
toward shared prevention goals. This means prioritising scale-up, quality delivery and close 
monitoring and evaluation of prevention strategies of those that have the best chance of 
success within the background on the epidemic scenario. Combination HIV prevention 
programmes need to include strategies that address socio-cultural and behavioural 
communication issues relating to sexual partnerships. They also need to provide safe 
biomedical interventions for MMC as well as topical microbicides and PrEP within the 
context of wider sexual and reproductive health services. This needs to include strategic 
condom programming, risk perceptions and awareness integrated through easily and  
widely available HCT services to ensure that the majority of person in need of treatment are 
supported and rapidly initiated on ART for maximum coverage. Optimistically, with an 
integrated combined response of HIV treatment and prevention, the benefits are expected to 
be substantial, particularly in high burden settings such as sub-Saharan Africa (figure 3) 
(Salomon, et al., 2005). An impact on HIV acquisition in a region with the highest burden of 
infection will impact on the disease globally. As agreed by the member states at the United 
Nations General Assembly Special Session on HIV/AIDS, countries need to continue with 
their efforts and scale up towards the goal of "universal access to comprehensive prevention 
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programmes, treatment, care and support" which complement the United Nations 
Millennium Development Goals to reduce child mortality, improve maternal health and 
combat HIV/AIDS, malaria and other major diseases. 
 
 
Fig. 3. Impact of treatment and prevention on new HIV infections in Africa (Salomon, et al., 
2005).  
8. References 
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. 
E., et al. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral 
microbicide, for the prevention of HIV infection in women. Science, 329(5996), 1168-
1174. 
Abdool Karim, S. S., Richardson, B. A., Ramjee, G., Hoffman, I. F., Chirenje, Z. M., Taha, T., 
et al. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the 
prevention of HIV infection in women. AIDS. 
Abu-Raddad, L. J., & Longini, I. M., Jr. (2008). No HIV stage is dominant in driving the HIV 
epidemic in sub-Saharan Africa. AIDS, 22(9), 1055-1061. 
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005). 
Randomized, controlled intervention trial of male circumcision for reduction of 
HIV infection risk: the ANRS 1265 Trial. PLoS Med, 2(11), e298. 
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., et al. (2007). Male 
circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised 
controlled trial. Lancet, 369(9562), 643-656. 
Broder, S. (2010). The development of antiretroviral therapy and its impact on the HIV-
1/AIDS pandemic. Antiviral Res, 85(1), 1-18. 
Celum, C., Wald, A., Hughes, J., Sanchez, J., Reid, S., Delany-Moretlwe, S., et al. (2008). 
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive 
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 
 
20
women and men who have sex with men: a randomised, double-blind, placebo-
controlled trial. Lancet, 371(9630), 2109-2119. 
Celum, C., Wald, A., Lingappa, J. R., Magaret, A. S., Wang, R. S., Mugo, N., et al. (2010). 
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. 
N Engl J Med, 362(5), 427-439. 
Coates, T. J., Richter, L., & Caceres, C. (2008). Behavioural strategies to reduce HIV 
transmission: how to make them work better. Lancet, 372(9639), 669-684. 
Donnell, D., Baeten, J. M., Kiarie, J., Thomas, K. K., Stevens, W., Cohen, C. R., et al. (2010). 
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a 
prospective cohort analysis. Lancet, 375(9731), 2092-2098. 
Dunkle, K. L., Jewkes, R., Nduna, M., Jama, N., Levin, J., Sikweyiya, Y., et al. (2007). 
Transactional sex with casual and main partners among young South African men 
in the rural Eastern Cape: prevalence, predictors, and associations with gender-
based violence. Soc Sci Med, 65(6), 1235-1248. 
Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., et al. (2008). 
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized 
controlled trial in Nigeria. PLoS One, 3(1), e1474. 
Ghys, P. D., Diallo, M. O., Ettiegne-Traore, V., Satten, G. A., Anoma, C. K., Maurice, C., et al. 
(2001). Effect of interventions to control sexually transmitted disease on the 
incidence of HIV infection in female sex workers. AIDS, 15(11), 1421-1431. 
Gouws, E., Stanecki, K. A., Lyerla, R., & Ghys, P. D. (2008). The epidemiology of HIV 
infection among young people aged 15-24 years in southern Africa. AIDS, 22 Suppl 
4, S5-16. 
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009). Universal 
voluntary HIV testing with immediate antiretroviral therapy as a strategy for 
elimination of HIV transmission: a mathematical model. Lancet, 373(9657), 48-57. 
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., et al. (2010). 
Preexposure chemoprophylaxis for HIV prevention in men who have sex with 
men. N Engl J Med, 363(27), 2587-2599. 
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., et al. (2007). 
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. 
Lancet, 369(9562), 657-666. 
Gray, R. H., Wawer, M. J., Brookmeyer, R., Sewankambo, N. K., Serwadda, D., Wabwire-
Mangen, F., et al. (2001). Probability of HIV-1 transmission per coital act in 
monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet, 
357(9263), 1149-1153. 
Hallett, T. B., Singh, K., Smith, J. A., White, R. G., Abu-Raddad, L. J., & Garnett, G. P. (2008). 
Understanding the impact of male circumcision interventions on the spread of HIV 
in southern Africa. PLoS ONE, 3(5), e2212. 
Harrison, A., Cleland, J., & Frohlich, J. (2008). Young people's sexual partnerships in 
KwaZulu-Natal, South Africa: patterns, contextual influences, and HIV risk. Stud 
Fam Plann, 39(4), 295-308. 
www.intechopen.com
 
HIV Epidemiology and Prevention 
 
21 
Hayes, R., Mosha, F., Nicoll, A., Grosskurth, H., Newell, J., Todd, J., et al. (1995). A 
community trial of the impact of improved sexually transmitted disease treatment 
on the HIV epidemic in rural Tanzania: 1. Design. AIDS, 9(8), 919-926. 
Horton, R., & Das, P. (2008). Putting prevention at the forefront of HIV/AIDS. Lancet, 
372(9637), 421-422. 
Jewkes, R., Dunkle, K., Nduna, M., Levin, J., Jama, N., Khuzwayo, N., et al. (2006). Factors 
associated with HIV sero-positivity in young, rural South African men. Int J 
Epidemiol, 35(6), 1455-1460. 
Johnson, B. T., Scott-Sheldon, L. A., Huedo-Medina, T. B., & Carey, M. P. (2011). 
Interventions to reduce sexual risk for human immunodeficiency virus in 
adolescents: a meta-analysis of trials, 1985-2008. Arch Pediatr Adolesc Med, 165(1), 
77-84. 
Joint United Nations Programme on HIV and AIDS and World Health Organization. (2007). 
Guidance on provider-initiated HIV testing and counselling in health facilities. 
ISBN 978 92 4 159556 8 (NLM classification: WC 503.1). 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO). (2007a). Practical Guidelines for Intensifying HIV Prevention: Towards 
Universal Access. ISBN 978 92 9173 557 0 (NLM classification: WC 503.2), Geneva. 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO). (2007b). WHO AND UNAIDS  announce recommendations from expert 
meeting on male circumcision for HIV prevention  
 http://data.unaids.org/pub/pressrelease/2007/20070328_pr_mc_recommendations_en.pdf. 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO). (2008). Report on the global HIV/AIDS epidemic 2008.  
 http://data.unaids.org/pub/GlobalReport/2008/JC1510_2008GlobalReport_en, Geneva. 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO). (2010). Global report: UNAIDS report on the global AIDS epidemic 2010. 
UNAIDS/10.11E | JC1958E  ISBN 978-92-9173-871-7 (NLM classification: WC 503.4) 
http://www.unaids.org/globalreport/Global_report.htm. 
Kalichman, S. C., Ntseane, D., Nthomang, K., Segwabe, M., Phorano, O., & Simbayi, L. C. 
(2007). Recent multiple sexual partners and HIV transmission risks among people 
living with HIV/AIDS in Botswana. Sex Transm Infect, 83(5), 371-375. 
Kamali, A., Byomire, H., Muwonge, C., Bakobaki, J., Rutterford, C., Okong, P., et al. (2010). 
A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal 
microbicide gel in sexually active women in Uganda. Sex Transm Infect, 86(3), 222-
226. 
Kamali, A., Kinsman, J., Nalweyiso, N., Mitchell, K., Kanyesigye, E., Kengeya-Kayondo, J. F., 
et al. (2002). A community randomized controlled trial to investigate impact of 
improved STD management and behavioural interventions on HIV incidence in 
rural Masaka, Uganda: trial design, methods and baseline findings. Trop Med Int 
Health, 7(12), 1053-1063. 
Kaul, R., Kimani, J., Nagelkerke, N. J., Fonck, K., Ngugi, E. N., Keli, F., et al. (2004). Monthly 
antibiotic chemoprophylaxis and incidence of sexually transmitted infections and 
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 
 
22
HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA, 
291(21), 2555-2562. 
Kenyon C, & Badri M. (2009). The role of concurrent sexual relationships in the spread of 
Sexually Transmitted Infections in young South Africans The Southern African 
Journal of HIV Medicine, 10(1), 29-36. 
Khumalo-Sakutukwa, G., Morin, S. F., Fritz, K., Charlebois, E. D., van Rooyen, H., 
Chingono, A., et al. (2008). Project Accept (HPTN 043): a community-based 
intervention to reduce HIV incidence in populations at risk for HIV in sub-Saharan 
Africa and Thailand. J Acquir Immune Defic Syndr, 49(4), 422-431. 
Kim, H. H., & Goldstein, M. (2009). High complication rates challenge the implementation of 
male circumcision for HIV prevention in Africa. Nat Clin Pract Urol, 6(2), 64-65. 
Lagarde, E., Taljaard, D., Puren, A., & Auvert, B. (2009). High rate of adverse events 
following circumcision of young male adults with the Tara KLamp technique: a 
randomised trial in South Africa. S Afr Med J, 99(3), 163-169. 
Leclerc-Madlala, S. (2008). Age-disparate and intergenerational sex in southern Africa: the 
dynamics of hypervulnerability. AIDS, 22 Suppl 4, S17-25. 
Lissouba, P., Taljaard, D., Rech, D., Doyle, S., Shabangu, D., Nhlapo, C., et al. (2010). A 
model for the roll-out of comprehensive adult male circumcision services in African 
low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. 
PLoS Med, 7(7), e1000309. 
Lurie, M., Williams, B. G., & Gouws, E. (1997). Circular Migration and Sexual Networking in 
rural KwaZulu/Natal: Implications for the Spread of HIV and other Sexually 
Transmitted Diseases Health Transition review, 7, 15-24. 
Moyo, W., Levandowski, B. A., MacPhail, C., Rees, H., & Pettifor, A. (2008). Consistent 
condom use in South African youth's most recent sexual relationships. AIDS Behav, 
12(3), 431-440. 
National Institute of Allergy and Infectious Diseases. (2011). QUESTIONS AND ANSWERS: 
The HPTN 052 Study: Preventing Sexual Transmission of HIV with Anti-HIV 
Drugs. http://www.niaid.nih.gov  
Peterson, L., Nanda, K., Opoku, B. K., Ampofo, W. K., Owusu-Amoako, M., Boakye, A. Y., et 
al. (2007). SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, 
double-blind, randomized, placebo-controlled trial in Ghana. PLoS One, 2(12), 
e1312. 
Pettifor, A., Macphail, C., Rees, H., & Cohen, M. (2008). HIV and sexual behavior among 
young people: the South African paradox. Sex Transm Dis, 35(10), 843-844. 
Pettifor, A. E., van der Straten, A., Dunbar, M. S., Shiboski, S. C., & Padian, N. S. (2004). 
Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. 
AIDS, 18(10), 1435-1442. 
Pilcher, C. D., Joaki, G., Hoffman, I. F., Martinson, F. E., Mapanje, C., Stewart, P. W., et al. 
(2007). Amplified transmission of HIV-1: comparison of HIV-1 concentrations in 
semen and blood during acute and chronic infection. AIDS, 21(13), 1723-1730. 
Pilcher, C. D., Tien, H. C., Eron, J. J., Jr., Vernazza, P. L., Leu, S. Y., Stewart, P. W., et al. 
(2004). Brief but efficient: acute HIV infection and the sexual transmission of HIV. J 
Infect Dis, 189(10), 1785-1792. 
www.intechopen.com
 
HIV Epidemiology and Prevention 
 
23 
Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., et 
al. (2000). Viral load and heterosexual transmission of human immunodeficiency 
virus type 1. Rakai Project Study Group. N Engl J Med, 342(13), 921-929. 
Rottingen, J. A., Cameron, D. W., & Garnett, G. P. (2001). A systematic review of the 
epidemiologic interactions between classic sexually transmitted diseases and HIV: 
how much really is known? Sex Transm Dis, 28(10), 579-597. 
Salomon, J. A., Hogan, D. R., Stover, J., Stanecki, K. A., Walker, N., Ghys, P. D., et al. (2005). 
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med, 2(1), 
e16. 
Schackman, B. R. (2010). Implementation science for the prevention and treatment of 
HIV/AIDS. J Acquir Immune Defic Syndr, 55 Suppl 1, S27-31. 
Siegfried, N., Muller, M., Deeks, J. J., & Volmink, J. (2009). Male circumcision for prevention 
of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev(2), CD003362. 
Sikweyiya, Y., & Jewkes, R. (2009). Force and temptation: contrasting South African men's 
accounts of coercion into sex by men and women. Cult Health Sex, 11(5), 529-541. 
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., et al. 
(2008). Efficacy of Carraguard for prevention of HIV infection in women in South 
Africa: a randomised, double-blind, placebo-controlled trial. Lancet, 372(9654), 
1977-1987. 
The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. (2000). Efficacy of 
voluntary HIV-1 counselling and testing in individuals and couples in Kenya, 
Tanzania, and Trinidad: a randomised trial. The Lancet, 356(9224), 103-112. 
Tobian, A. A., & Quinn, T. C. (2009). Herpes simplex virus type 2 and syphilis infections 
with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV 
AIDS, 4(4), 294-299. 
Tsai, C. C., Emau, P., Sun, J. C., Beck, T. W., Tran, C. A., Follis, K. E., et al. (2000). Post-
exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model 
for protection from HIV infection. J Med Primatol, 29(3-4), 248-258. 
United Nations General Assembly. (2001). Declaration of Commitment on HIV/AIDS. New 
York, United Nations. . http://www.unaids.org/en/AboutUNAIDS/Goals/UNGASS. 
United Nations Millineum Development Goals. (2000). New York, United Nations. 
http://www.un.org/millenniumgoals/aids.shtml, . 
Van Damme, L., Govinden, R., Mirembe, F. M., Guedou, F., Solomon, S., Becker, M. L., et al. 
(2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal 
HIV transmission. N Engl J Med, 359(5), 463-472. 
Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., et al. (2002). 
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in 
female sex workers: a randomised controlled trial. Lancet, 360(9338), 971-977. 
Van Rompay, K. K. (2010). Evaluation of antiretrovirals in animal models of HIV infection. 
Antiviral Res, 85(1), 159-175. 
Van Rompay, K. K., Singh, R. P., Brignolo, L. L., Lawson, J. R., Schmidt, K. A., Pahar, B., et 
al. (2004). The clinical benefits of tenofovir for simian immunodeficiency virus-
infected macaques are larger than predicted by its effects on standard viral and 
immunologic parameters. J Acquir Immune Defic Syndr, 36(4), 900-914. 
www.intechopen.com
 
HIV-Infection – Impact, Awareness and Social Implications of Living with HIV/AIDS 
 
24
Van Tieua, H., & Koblina, B. (2009). HIV, alcohol, and noninjection drug use. Current 
Opinion in HIV and AIDS 4, 314-318. 
Wald, A., & Link, K. (2002). Risk of human immunodeficiency virus infection in herpes 
simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis, 185(1), 45-52. 
Watson-Jones, D., Weiss, H. A., Rusizoka, M., Changalucha, J., Baisley, K., Mugeye, K., et al. 
(2008). Effect of herpes simplex suppression on incidence of HIV among women in 
Tanzania. N Engl J Med, 358(15), 1560-1571. 
Wawer, M. J., Gray, R. H., Sewankambo, N. K., Serwadda, D., Paxton, L., Berkley, S., et al. 
(1998). A randomized, community trial of intensive sexually transmitted disease 
control for AIDS prevention, Rakai, Uganda. AIDS, 12(10), 1211-1225. 
Weiss, H. A., Dickson, K. E., Agot, K., & Hankins, C. A. (2010). Male circumcision for HIV 
prevention: current research and programmatic issues. AIDS, 24 Suppl 4, S61-69. 
Williams, B. G., Lloyd-Smith, J. O., Gouws, E., Hankins, C., Getz, W. M., Hargrove, J., et al. 
(2006). The potential impact of male circumcision on HIV in Sub-Saharan Africa. 
PLoS Med, 3(7), e262. 
Wilson, D., & Halperin, D. T. (2008). "Know your epidemic, know your response": a useful 
approach, if we get it right. Lancet, 372(9637), 423-426. 
World Health Organization. (2009). Rapid advice: antiretroviral therapy for HIV infection in 
adults and adolescents -November 2009. ISBN 978 92 4 159895 8,  
 http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf. 
Zablotska, I. B., Gray, R. H., Koenig, M. A., Serwadda, D., Nalugoda, F., Kigozi, G., et al. 
(2009). Alcohol use, intimate partner violence, sexual coercion and HIV among 
women aged 15-24 in Rakai, Uganda. AIDS Behav, 13(2), 225-233. 
www.intechopen.com
HIV-infection - Impact, Awareness and Social Implications of living
with HIV/AIDS
Edited by Dr. Eugenia Barros
ISBN 978-953-307-343-9
Hard cover, 336 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The past few decades have seen the escalation of HIV-infections and the 'frantic' search for new drugs to treat
the millions of people that live with HIV-AIDS. However because HIV-AIDS cannot be cured, but only controlled
with drugs, and the Antiretroviral (ARV) treatment itself results in some undesirable conditions, it is important to
generate wider awareness of the plight of people living with this condition. This book attempts to provide
information of the initiatives that have been used, successfully or unsuccessfully, to both prevent and combat
this 'pandemic' taking into consideration the social, economic, cultural and educational aspects that involve
individuals, communities and the countries affected.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ayesha B.M. Kharsany and Quarraisha Abdool Karim (2011). HIV Epidemiology and Prevention, HIV-infection -
Impact, Awareness and Social Implications of living with HIV/AIDS, Dr. Eugenia Barros (Ed.), ISBN: 978-953-
307-343-9, InTech, Available from: http://www.intechopen.com/books/hiv-infection-impact-awareness-and-
social-implications-of-living-with-hiv-aids/hiv-epidemiology-and-prevention
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
